367 related articles for article (PubMed ID: 3142490)
21. General pharmacological properties of muroctasin.
Kojima H; Hirohashi M; Kasai Y; Takasuna K; Fukumoto C; Akashi A
Arzneimittelforschung; 1988 Jul; 38(7A):1002-9. PubMed ID: 3190791
[TBL] [Abstract][Full Text] [Related]
22. Antigenicity study of muroctasin.
Yamaguchi F; Hattori H; Wagai N; Tsukada W
Arzneimittelforschung; 1988 Jul; 38(7A):1034-7. PubMed ID: 3190797
[TBL] [Abstract][Full Text] [Related]
23. Induction of colony-stimulating factor and stimulation of stem cell proliferation by injection of muroctasin.
Yamaguchi F; Akasaki M; Tsukada W
Arzneimittelforschung; 1988 Jul; 38(7A):980-3. PubMed ID: 3263869
[TBL] [Abstract][Full Text] [Related]
24. Restorative activity of muroctasin on leukopenia associated with anticancer treatment.
Tsubura E; Nomura T; Niitani H; Osamura S; Okawa T; Tanaka M; Ota K; Nishikawa H; Masaoka T; Fukuoka M
Arzneimittelforschung; 1988 Jul; 38(7A):1070-4. PubMed ID: 3190800
[TBL] [Abstract][Full Text] [Related]
25. Effects of muroctasin on the activities of drug metabolizing enzymes in liver microsomes of rats.
Kamataki T; Komori M; Iwasaki M; Ohi H; Kitada M; Miura T; Ono K
Arzneimittelforschung; 1988 Jul; 38(7A):1019-22. PubMed ID: 3263867
[TBL] [Abstract][Full Text] [Related]
26. Comparative analysis of the priming effect of human interferon-gamma, -alpha, and -beta on synergism with muramyl dipeptide analog for anti-tumor expression of human blood monocytes.
Utsugi T; Sone S
J Immunol; 1986 Feb; 136(3):1117-22. PubMed ID: 3079797
[TBL] [Abstract][Full Text] [Related]
27. Effect of cisplatin, lipopolysaccharide, muramyl dipeptide and recombinant interferon-gamma on murine macrophages in vitro. I. Macrophage-mediated tumor cell lysis.
Geetha B; Sodhi A
Nat Immun Cell Growth Regul; 1989; 8(2):100-7. PubMed ID: 2503714
[TBL] [Abstract][Full Text] [Related]
28. Production of interleukin-6 from macrophages by MDP-Lys (L 18), romurtide.
Shimoda K; Okamura S; Harada N; Omori F; Niho Y
Res Commun Chem Pathol Pharmacol; 1990 Dec; 70(3):289-96. PubMed ID: 2093210
[TBL] [Abstract][Full Text] [Related]
29. Beneficial effect of muroctasin on experimental leukopenia induced by cyclophosphamide or irradiation in mice.
Nakajima R; Ishida Y; Yamaguchi F; Otani T; Ono Y; Nomura M; Une T; Osada Y
Arzneimittelforschung; 1988 Jul; 38(7A):986-92. PubMed ID: 3263871
[TBL] [Abstract][Full Text] [Related]
30. Physico-chemical properties of muroctasin.
Moroi R; Yamazaki K; Hirota T; Watanabe S; Kataoka K; Ichinose M
Arzneimittelforschung; 1988 Jul; 38(7A):953-9. PubMed ID: 3190802
[TBL] [Abstract][Full Text] [Related]
31. Acute toxicity of muroctasin in mice, rats and dogs.
Ono Y; Iwasaki T; Furuhama K; Onodera T
Arzneimittelforschung; 1988 Jul; 38(7A):1022-4. PubMed ID: 3190794
[TBL] [Abstract][Full Text] [Related]
32. Synergistic induction of cytotoxicity in macrophages by murine interferon-gamma and biological response modifiers derived from microorganisms.
Nagao S; Sato K; Osada Y
Cancer Immunol Immunother; 1986; 23(1):41-5. PubMed ID: 3094943
[TBL] [Abstract][Full Text] [Related]
33. Acute and chronic polyarthritis induced by an aqueous form of 6-O-acyl and N-acyl derivatives of N-acetylmuramyl-L-alanyl-D-isoglutamine in euthymic rats and athymic nude rats.
Kohashi O; Kohashi Y; Shigematsu N; Ozawa A; Kotani S
Lab Invest; 1986 Sep; 55(3):337-46. PubMed ID: 3489128
[TBL] [Abstract][Full Text] [Related]
34. Muroctasin. A new muramyl dipeptide derivative, MDP-Lys(L18).
Arzneimittelforschung; 1988 Jul; 38(7A):951-1074. PubMed ID: 3190801
[No Abstract] [Full Text] [Related]
35. Induction of tumoricidal macrophages and production of cytokines by synthetic muramyl dipeptide analogues.
Saiki I; Saito S; Fujita C; Ishida H; Iida J; Murata J; Hasegawa A; Azuma I
Vaccine; 1988 Jun; 6(3):238-44. PubMed ID: 2844032
[TBL] [Abstract][Full Text] [Related]
36. Phase I study and clinical pharmacological study of muroctasin.
Ichihara N; Kanazawa R; Sasaki S; Ono K; Otani T; Yamaguchi F; Une T
Arzneimittelforschung; 1988 Jul; 38(7A):1043-69. PubMed ID: 3263868
[TBL] [Abstract][Full Text] [Related]
37. Synergism between human recombinant gamma-interferon and muramyl dipeptide encapsulated in liposomes for activation of antitumor properties in human blood monocytes.
Saiki I; Sone S; Fogler WE; Kleinerman ES; Lopez-Berestein G; Fidler IJ
Cancer Res; 1985 Dec; 45(12 Pt 1):6188-93. PubMed ID: 3933823
[TBL] [Abstract][Full Text] [Related]
38. Metabolic disposition of 14C-muroctasin in laboratory animals.
Ono K; Masayasu H; Hashimoto F; Yamada M; Takegoshi T
Arzneimittelforschung; 1988 Jul; 38(7A):1009-14. PubMed ID: 3190792
[TBL] [Abstract][Full Text] [Related]
39. Augmentation of immune responses by a muramyl dipeptide analog, MDP-Lys(L18).
Akasaki M; Takashi T; Kita Y; Tsukada W
Agents Actions; 1987 Oct; 22(1-2):144-50. PubMed ID: 3318323
[TBL] [Abstract][Full Text] [Related]
40. A novel immunostimulator, N-[alpha-O-benzyl-N-(acetylmuramyl)-L-alanyl-D-isoglutaminyl]-N6-trans-(m-nitrocinnamoyl)-L-lysine, and its adjuvancy on the hepatitis B surface antigen.
Yang HZ; Xu S; Liao XY; Zhang SD; Liang ZL; Liu BH; Bai JY; Jiang C; Ding J; Cheng GF; Liu G
J Med Chem; 2005 Aug; 48(16):5112-22. PubMed ID: 16078831
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
